

# Caterina Bartolacci

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8139876/publications.pdf>

Version: 2024-02-01

8  
papers

189  
citations

1307594

7  
h-index

1720034

7  
g-index

9  
all docs

9  
docs citations

9  
times ranked

289  
citing authors

#	ARTICLE	IF	CITATIONS
1	Resveratrol fuels HER2 and ER $\pm$ -positive breast cancer behaving as proteasome inhibitor. <i>Aging</i> , 2017, 9, 508-523.	3.1	40
2	Lipid Metabolism Regulates Oxidative Stress and Ferroptosis in RAS-Driven Cancers: A Perspective on Cancer Progression and Therapy. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 706650.	3.5	32
3	Phage-Based Anti-HER2 Vaccination Can Circumvent Immune Tolerance against Breast Cancer. <i>Cancer Immunology Research</i> , 2018, 6, 1486-1498.	3.4	25
4	Irreversible inhibition of $\hat{1}$ 6HER2 is necessary to suppress $\hat{1}$ 6HER2-positive breast carcinomas resistant to Lapatinib. <i>Cancer Letters</i> , 2016, 381, 76-84.	7.2	23
5	InÂvitro and inÂvivo studies of gold(I) azolate/phosphane complexes for the treatment of basal like breast cancer. <i>European Journal of Medicinal Chemistry</i> , 2018, 155, 418-427.	5.5	23
6	Medium-Chain Acyl-CoA Dehydrogenase Protects Mitochondria from Lipid Peroxidation in Glioblastoma. <i>Cancer Discovery</i> , 2021, 11, 2904-2923.	9.4	23
7	Walking a Tightrope: A Perspective of Resveratrol Effects on Breast Cancer. <i>Current Protein and Peptide Science</i> , 2018, 19, 311-322.	1.4	13
8	Ferroptosis: A Specific Vulnerability of RAS-Driven Cancers?. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	7